Anteris Technologies Global (NASDAQ:AVR) Coverage Initiated by Analysts at Wells Fargo & Company

Wells Fargo & Company began coverage on shares of Anteris Technologies Global (NASDAQ:AVR) in a research report sent to investors on Wednesday, Marketbeat reports. The brokerage issued an overweight rating and a $16.00 target price on the stock.

Several other research firms have also recently commented on AVR. Weiss Ratings restated a “sell (e+)” rating on shares of Anteris Technologies Global in a research report on Monday, December 29th. Cantor Fitzgerald raised Anteris Technologies Global to a “strong-buy” rating in a report on Wednesday, March 4th. Finally, Lake Street Capital reiterated a “buy” rating and set a $15.00 price objective on shares of Anteris Technologies Global in a research report on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.50.

Anteris Technologies Global Stock Performance

AVR stock opened at $6.69 on Wednesday. Anteris Technologies Global has a 1 year low of $2.34 and a 1 year high of $7.90. The stock has a market capitalization of $275.63 million, a price-to-earnings ratio of -2.61 and a beta of 1.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.73 and a current ratio of 0.73. The stock’s fifty day moving average is $5.72 and its two-hundred day moving average is $4.98.

Anteris Technologies Global (NASDAQ:AVR) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.75) EPS for the quarter. The firm had revenue of $0.31 million for the quarter. Anteris Technologies Global had a negative return on equity of 536.04% and a negative net margin of 4,921.27%. On average, research analysts predict that Anteris Technologies Global will post -2.66 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder L1 Capital Pty Ltd bought 5,000,000 shares of the business’s stock in a transaction on Thursday, January 22nd. The stock was purchased at an average cost of $5.75 per share, for a total transaction of $28,750,000.00. Following the completion of the transaction, the insider directly owned 13,219,814 shares of the company’s stock, valued at approximately $76,013,930.50. This trade represents a 60.83% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.50% of the stock is owned by company insiders.

Institutional Trading of Anteris Technologies Global

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Marex Group plc bought a new position in Anteris Technologies Global during the second quarter valued at about $641,000. Affinity Asset Advisors LLC raised its position in Anteris Technologies Global by 9.0% in the second quarter. Affinity Asset Advisors LLC now owns 425,000 shares of the company’s stock worth $1,611,000 after acquiring an additional 35,000 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Anteris Technologies Global in the 2nd quarter valued at about $49,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Anteris Technologies Global by 34.4% in the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,780 shares of the company’s stock valued at $71,000 after acquiring an additional 4,036 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Anteris Technologies Global by 35.7% during the 3rd quarter. Bank of America Corp DE now owns 10,631 shares of the company’s stock valued at $48,000 after purchasing an additional 2,798 shares in the last quarter.

Anteris Technologies Global Company Profile

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.